

Recombinant Human LILRB4/CD85k/ILT3 Protein (His Tag)

Catalog No. PKSH033603

Note: Centrifuge before opening to ensure complete recovery of vial contents.


Description

Synonyms	Leukocyte immunoglobulin-like receptor subfamily B member 4; Mast cell surface glycoprotein Gp49B; CD85k; Lilrb4; Gp49b
Species	Human
Expression Host	HEK293 Cells
Sequence	Gln22-Glu259
Accession	Q8NHJ6
Calculated Molecular Weight	27.1 kDa
Observed molecular weight	37 kDa
Tag	C-His
Bioactivity	Not validated for activity

Properties

Purity	> 95 % as determined by reducing SDS-PAGE.
Endotoxin	< 1.0 EU per µg of the protein as determined by the LAL method.
Storage	Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.
Shipping	This product is provided as lyophilized powder which is shipped with ice packs.
Formulation	Lyophilized from a 0.2 µm filtered solution of PBS, pH 7.4. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Please refer to the specific buffer information in the printed manual.
Reconstitution	Please refer to the printed manual for detailed information.

Data



> 95 % as determined by reducing SDS-PAGE.

Background

Mouse Leukocyte Immunoglobulin-like Receptor Subfamily B Member 4 (LILRB4/CD85k/ILT3) is an approximately

For Research Use Only

transmembrane glycoprotein that negatively regulates immune cell activation. Mouse LILRB4 consists of a 215 amino acid (aa) extracellular domain with two Ig-like domains; a 22 aa transmembrane segment; and a 75 aa cytoplasmic domain with 3 immunoreceptor tyrosine-based inhibitory motifs (ITIM). Within the ECD; mouse LILRB4 shares 45% and 77% aa sequence identity with human and rat LILRB4; respectively. Alternative splicing of mouse LILRB4 generates a potentially soluble isoform that lacks the transmembrane segment. LILRB4 is expressed on dendritic cells (DC); monocytes; macrophages; and vascular endothelial cells (EC). Ligation of LILRB4 triggers ITIM-mediated inhibition of cellactivating signaling; leading to enhanced immune tolerance and reduced allogeneic graft rejection. Soluble LILRB4 induces the differentiation of CD8+ T suppressor cells (Ts) that can inhibit the effector functions of CD4+ Th cells and CD8+ CTL. In turn; CD8+ Ts cells induce LILRB4 up-regulation and a tolerogenic phenotype in monocytes; DC; and EC.